LQDA Liquidia Corporation
USHealthcareAs of 2026-07-10 16:00
Why LQDA matters now
Liquidia Corporation (LQDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $77.93 with -4.32% on the session and $6.93B in market capitalization; recent performance reads 1-month +18.49% and YTD +106.06%.
The latest financial table shown here is Q1 2026, with revenue of $132.9M, net income of $52.9M, and EPS of $0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.7%.
The latest indexable market news headline is "4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $68.00; recent insider activity includes Manning Paul B filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
57.60
P/S
21.94
EV/EBITDA
116.78
DCF Value
$-83.75
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.8%
Operating Margin
15.8%
Net Margin
7.7%
ROE
46.8%
ROA
5.6%
ROIC
12.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $132.9M | $52.9M | $0.52 |
| Q4 2025 | $92.0M | $14.6M | $0.15 |
| FY 2025 | $158.3M | $-68.9M | $-0.80 |
| Q3 2025 | $54.3M | $-3.5M | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$68.00
Target (Median)
$68.00
Target Range
$60.00 - $75.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.59
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.